Observational Study

Minimally invasive cytoreductive surgery in advanced ovarian cancer: A nonselected consecutive series of robotic-assisted cases

Natalie Shammas*, Rosa Avila, Christopher Khatchadourian, Erland Laurence Spencer-Smith, Lisa Stern and Steven Vasilev

Published: 28 April, 2023 | Volume 6 - Issue 2 | Pages: 032-037

The gold standard for advanced-stage ovarian cancer surgery entails exploration via a midline vertical laparotomy. Studies have shown that minimally invasive surgery (MIS) can be a safe and effective method for the surgical management of early ovarian cancer. In some cases, MIS can also be selectively used for cytoreductive surgery in cases with advanced-stage ovarian cancer. The robotic platform has the potential to provide similar outcomes to the laparotomy-based standard of care in advanced complex surgery while accelerating recovery, minimizing morbidity, and reducing perioperative complications. The primary objective of this study was to evaluate surgical and perioperative outcomes in patients with advanced ovarian carcinoma who underwent robotic-assisted cytoreduction. A chart review of a nonselected consecutive series of all patients undergoing surgical management of advanced ovarian cancer between 7/1/2017 and 12/31/2021 was conducted. All patients that were diagnosed with Stage III to IV ovarian cancer between the timeframe underwent robotic-assisted cytoreductive surgery at two urban community teaching hospitals in Los Angeles. Twenty-five patients were identified and included in this study. All surgeries were performed by a single surgeon. Optimal or complete CRS was achieved in 96% of the patients (24 of 25 cases). Seven (28%) underwent primary cytoreduction (PCRS) and 18 (72%) underwent interval cytoreduction (ICRS). The estimated median blood loss was 100 mL (25-500 mL), the median operative time was 5.9 hours (3.1-10.5 hours), and the conversion rate to open laparotomy was 0%. There were no intraoperative complications and the readmission rate within 30 days was 4% (1 patient) for ileus, which was managed conservatively. Currently, 64% of the patients in the case series remain alive. The median survival has not been reached. The median follow-up is 4.08 years. Results presented from this nonselected, consecutive case series illustrate how a minimally invasive robotic approach can be safely used in place of the standard exploratory laparotomy for ovarian cytoreduction.

Read Full Article HTML DOI: 10.29328/journal.cjog.1001126 Cite this Article Read Full Article PDF


Cytoreduction; Laparotomy; Ovarian cancer; Robotic-assisted


  1. Cummings M, Nicolais O, Shahin M. Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction. Diagnostics (Basel). 2022 Apr 14;12(4):988. doi: 10.3390/diagnostics12040988. PMID: 35454036; PMCID: PMC9026414.
  2. Xu Z, Becerra AZ, Justiniano CF, Aquina CT, Fleming FJ, Boscoe FP, Schymura MJ, Sinno AK, Chaoul J, Morrow GR, Minasian L, Temkin SM. Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer. J Surg Res. 2020 Feb;246:34-41. doi: 10.1016/j.jss.2019.08.027. Epub 2019 Sep 24. PMID: 31561176; PMCID: PMC6917987.
  3. Smith CG, Davenport DL, Gorski J, McDowell A, Burgess BT, Fredericks TI, Baldwin LA, Miller RW, DeSimone CP, Dietrich CS 3rd, Gallion HH, Pavlik EJ, van Nagell JR Jr, Ueland FR. Clinical Factors Associated with Longer Hospital Stay Following Ovarian Cancer Surgery. Healthcare (Basel). 2019 Jul 3;7(3):85. doi: 10.3390/healthcare7030085. PMID: 31277282; PMCID: PMC6787623.
  4. Arora T, Mullangi S, Lekkala MR. Ovarian Cancer. 2023 Jan 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 33620837.
  5. Roett MA, Evans P. Ovarian cancer: an overview. Am Fam Physician. 2009 Sep 15;80(6):609-16. PMID: 19817326.
  6. Huober J, Meyer A, Wagner U, Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J Cancer Res Clin Oncol. 2002 Mar;128(3):153-60. doi: 10.1007/s00432-001-0312-3. Epub 2002 Jan 29. PMID: 11935302.
  7. Nezhat FR. Laparoscopic cytoreduction for primary advanced or recurrent ovarian, fallopian tube, and peritoneal malignancies. Gynecologic oncology. 2008; 108(3), S60–S61.
  8. Cummings M, Nicolais O, Shahin M. Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction. Diagnostics (Basel). 2022 Apr 14;12(4):988. doi: 10.3390/diagnostics12040988. PMID: 35454036; PMCID: PMC9026414.
  9. Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, Margariti PA, Chiantera V, Costantini B, Gueli Alletti S, Cosentino F, Scambia G. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020 Nov;30(11):1657-1664. doi: 10.1136/ijgc-2020-001640. Epub 2020 Oct 7. PMID: 33028623.
  10. Gallotta V, Cicero C, Conte C, Vizzielli G, Petrillo M, Fagotti A, Chiantera V, Costantini B, Scambia G, Ferrandina G. Robotic Versus Laparoscopic Staging for Early Ovarian Cancer: A Case-Matched Control Study. J Minim Invasive Gynecol. 2017 Feb;24(2):293-298. doi: 10.1016/j.jmig.2016.11.004. Epub 2016 Nov 14. PMID: 27856387.
  11. Carbajal-Mamani SL, Schweer D, Markham MJ, Esnakula AK, Grajo JR, Castagno JC, Cardenas-Goicoechea J. Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study. Obstet Gynecol Sci. 2020 Mar;63(2):150-157. doi: 10.5468/ogs.2020.63.2.150. Epub 2020 Feb 10. PMID: 32206654; PMCID: PMC7073361.
  12. Rabinovich A. Robotic surgery for ovarian cancers: individualization of the surgical approach to select ovarian cancer patients. Int J Med Robot. 2016 Sep;12(3):547-53. doi: 10.1002/rcs.1684. Epub 2015 Jul 15. PMID: 26173832.
  13. Kremer KM, Lee J, Carlson MJ, Lococo SJ, Miller DS, Lea JS. Practice patterns using minimally invasive surgery for the treatment of ovarian cancer: A survey of physician members of the Society of Gynecologic Oncologists. Gynecol Oncol Rep. 2020 Aug 3;33:100617. doi: 10.1016/j.gore.2020.100617. PMID: 32793791; PMCID: PMC7415833.
  14. Zeng S, Yu Y, Cui Y, Liu B, Jin X, Li Z, Liu L. Efficacy and Safety of Minimally Invasive Surgery Versus Open Laparotomy for Interval Debulking Surgery of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A Systematic Review and A Meta-Analysis. Front Oncol. 2022 Jul 18;12:900256. doi: 10.3389/fonc.2022.900256. PMID: 35924170; PMCID: PMC9341245.
  15. Nitecki R, Rauh-Hain JA, Melamed A, Scambia G, Pareja R, Coleman RL, Ramirez PT, Fagotti A. Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE). Int J Gynecol Cancer. 2020 Sep;30(9):1450-1454. doi: 10.1136/ijgc-2020-001584. Epub 2020 Jul 20. PMID: 32690591; PMCID: PMC7493891.
  16. Xu Z, Becerra AZ, Justiniano CF, Aquina CT, Fleming FJ, Boscoe FP, Schymura MJ, Sinno AK, Chaoul J, Morrow GR, Minasian L, Temkin SM. Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer. J Surg Res. 2020 Feb;246:34-41. doi: 10.1016/j.jss.2019.08.027. Epub 2019 Sep 24. PMID: 31561176; PMCID: PMC6917987.
  17. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002 Mar 1;20(5):1248-59. doi: 10.1200/JCO.2002.20.5.1248. PMID: 11870167.
  18. Wakabayashi MT, Lin PS, Hakim AA. The role of cytoreductive/debulking surgery in ovarian cancer. J Natl Compr Canc Netw. 2008 Sep;6(8):803-10; quiz 811. doi: 10.6004/jnccn.2008.0060. PMID: 18926091.
  19. Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L, Colombo N, Landoni F, Minig L, Biffi R, Radice D, Maggioni A. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol. 2010 Nov;119(2):259-64. doi: 10.1016/j.ygyno.2010.07.032. Epub 2010 Aug 25. PMID: 20800269.
  20. Bacalbasa N, Dima S, Balescu I, David L, Brasoveanu V, Popescu I. Results of Primary Cytoreductive Surgery in Advanced-stage Epithelial Ovarian Cancer: A Single-center Experience. Anticancer Res. 2015 Jul;35(7):4099-104. PMID: 26124361.
  21. Chi DS, Schwartz PE. Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer. Gynecol Oncol. 2008 Dec;111(3):391-9. doi: 10.1016/j.ygyno.2008.07.058. PMID: 19041036.
  22. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727-33. PMID: 526911.
  23. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015 Jul 18;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6. Epub 2015 May 19. PMID: 26002111.
  24. Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol. 2001 Sep;82(3):435-41. doi: 10.1006/gyno.2001.6313. PMID: 11520137.
  25. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1992 Nov;47(2):159-66. doi: 10.1016/0090-8258(92)90100-w. PMID: 1468693.
  26. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2007 Jul;106(1):69-74. doi: 10.1016/j.ygyno.2007.02.026. Epub 2007 Mar 29. PMID: 17397910.
  27. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 2008 Feb;108(2):276-81. doi: 10.1016/j.ygyno.2007.10.022. Epub 2007 Dec 11. PMID: 18063020.
  28. Lecointre L, Pellerin M, Venkatasamy A, Fabacher T, Eberst L, Gantzer J, Jochum F, Faller É, Boisramé T, Querleu D, Akladios C. Complete Laparoscopic Interval Debulking Surgery for Advanced Ovarian Cancer Achieves Similar Survival Outcomes to Open Approach: A Propensity-Matched Study. J Invest Surg. 2022 Jun;35(6):1394-1401. doi: 10.1080/08941939.2022.2045396. Epub 2022 Mar 1. PMID: 35227150.
  29. Abitbol J, Gotlieb W, Zeng Z, Ramanakumar A, Kessous R, Kogan L, Pare-Miron V, Rombaldi M, Salvador S, Kucukyazici B, Brin S, How J, Lau S. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy. Int J Gynecol Cancer. 2019 Nov;29(9):1341-1347. doi: 10.1136/ijgc-2019-000413. Epub 2019 Oct 9. PMID: 31601648.
  30. Deo S, Ray M, Bansal B, Bhoriwal S, Bhatnagar S, Garg R, Gupta N, Sharma A, Kumar L, Thulkar S, Dhamija E, Mathur S, Das P. Feasibility and outcomes of cytoreductive surgery and HIPEC for peritoneal surface malignancies in low- and middle-income countries: a single-center experience of 232 cases. World J Surg Oncol. 2021 Jun 5;19(1):164. doi: 10.1186/s12957-021-02276-5. PMID: 34090452; PMCID: PMC8180169.
  31. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998 May;69(2):103-8. doi: 10.1006/gyno.1998.4955. PMID: 9600815.
  32. Corry E, Bartels H, Mulhall J, Grundy J, Mulsow J, Brennan D. 433 Determining the haematological morbidity associated with cytoreductive surgery. Poster. A179.2-A179. https://doi.org/10.1136/ijgc-2020-IGCS.375
  33. Feuer GA, Lakhi N, Barker J, Salmieri S, Burrell M. Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach. Gynecol Oncol. 2013 Dec;131(3):520-4. doi: 10.1016/j.ygyno.2013.09.022. Epub 2013 Sep 27. PMID: 24080421.
  34. Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, Tortorella L, Scambia G. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer. 2016 May;59:22-33. doi: 10.1016/j.ejca.2016.01.017. Epub 2016 Mar 19. PMID: 26998845.
  35. Kim NY, Jung DC, Lee JY, Han KH, Oh YT. CT-Based Fagotti Scoring System for Non-Invasive Prediction of Cytoreduction Surgery Outcome in Patients with Advanced Ovarian Cancer. Korean J Radiol. 2021 Sep;22(9):1481-1489. doi: 10.3348/kjr.2020.1477. Epub 2021 May 26. PMID: 34132077; PMCID: PMC8390820.

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?